Physician profile
Jack Saunders
NPI 1801175807
$2,793.30
in general payments reported to CMS, 2019-2025
21 companies · $696 in 2025
The $696 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $619 · 2022: $208 · 2023: $518 · 2024: $753 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,650 · Education: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,649.94 |
| Education | $316.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $663.09 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $430.17 | 2021-2025 | |
| Janssen Biotech, INC. | $358.78 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $352.11 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Abbvie INC. | $291.15 | 2021-2025 | |
| Lilly USA, LLC | $110.64 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $102.46 | 2021-2023 | Dupixent |
| Arcutis Biotherapeutics, INC. | $86.17 | 2023-2025 | Zoryve |
| Incyte Corporation | $54.15 | 2022-2023 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $53.00 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $47.40 | 2021-2025 | Aklief |
| Genzyme Corporation | $37.09 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $36.50 | 2021 | |
| Organon LLC | $30.87 | 2025 | Vtama |
| Pfizer INC. | $30.32 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $23.42 | 2022 | |
| Botanix Sb INC | $21.20 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $19.57 | 2024 | Vtama |
| Amgen INC. | $19.07 | 2024 | Otezla |
| Smith+Nephew, INC. | $14.42 | 2021 | |
| Epi Health, LLC | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.